Acting on its authorization to acquire up to 10% of its shares,
Lundbeck's Supervisory Board has resolved to initiate a share buyback
program. Under the program Lundbeck will buy own shares for an amount
of up to DKK 6 billion, cf. stock exchange announcement number 166
dated 17 August 2005. The buyback program is expected to be completed
by the end of 2008.
During any one single trading day a maximum of 25% of the average
daily trading volume of Lundbeck shares on OMX Nordic Exchange
Copenhagen, calculated over 20 days prior to each trading date, will
be bought back, as the share buyback program is implemented in
accordance with the provisions of the European Commission's
regulation no. 2273/2003 of December 22, 2003.
At least once every seven trading days, Lundbeck will issue an
announcement in respect of the transactions made under the program.
The following transactions have been made under the program:
No. of shares Average Transaction value
purchase price (DKK)
(DKK)
Accumulated, last 28,039,762 135.0087 3,785,612,102
announcement
27 February 2008 60,400 117.4717 7,095,289.87
28 February 2008 59,100 116.2111 6,868,073.32
29 February 2008 60,500 116.7154 7,061,278.88
3 March 2008 63,100 117.5458 7,417,137.72
4 March 2008 63,800 113.1666 7,220,026.21
5 March 2008 71,300 110.1045 7,850,449.26
6 March 2008 50,300 105.9730 5,330,439.89
Accumulated under the 28,468,262 134.6923 3,834,454,797
program
Following the above buyback it is hereby announced that Lundbeck owns
a total of 9,311,475 own shares at a nominal value of DKK 5, equal to
4.49% of the total number of 207,279,631 shares.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Anders Schroll
Director Head of Communication
+45 36 43 30 79 +45 36 43 20 81
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
Stock Exchange Release No 328 - 6 March 2008
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
